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Abstract Experienced robotic surgeons report lower
estimated blood loss (EBL) and transfusion rates with
similar clinical outcomes for robotic assisted laparoscopic
radical prostatectomy (RALP) compared to open radical
retropubic prostatectomy (RRP). We reviewed our expe-
rience with RALP to investigate how to counsel
overweight and obese patients being considered for RALP
regarding risk of major perioperative complications,
oncological outcomes, and short-term recovery. We
reviewed the data on 1,513 patients who underwent RALP
by one of four experienced robotic surgeons between June
2003 and November 2006. These patients were categorized
as normal, overweight, obese, and severely obese based on
body mass index (BMI). Of these patients, 361 (23.9%) had
a BMI under 25, 794 (52.5%) had a BMI between 25 and
30 (overweight), 290 (19.2%) had a BMI between 30 and
35 (obese), and 68 (4.5%) had a BMI over 35 (severely
obese). Records were examined and analyzed with respect
to BMI for major intra- and perioperative complications,
operative time, margin status, EBL, transfusion rates, and
length of hospital stay. Increasing BMI was associated with
longer operative time, with mean operative times of 2.7,
2.8, 3.1, and 3.3 h for normal, overweight, obese and
severely obese patients, respectively (P \ 0.0001). Higher
blood loss, though not clinically significant, was also
associated with increased BMI, with obese and severely
obese patients losing a median of 250 mL of blood com-
pared to 200 mL in overweight and non-overweight
patients (P \ 0.0001). Transfusion rates, intra- and peri-
operative complications, margin status, and length of stay
were not found to be associated with BMI group. Robotic
assisted laparoscopic radical prostatectomy in experienced
hands can be safely recommended to eligible patients
regardless of BMI status.
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Introduction
The increase in prostate specific antigen (PSA) testing in
the United States since the early 1990s has resulted in an
increase in prostate cancer incidence along with an asso-
ciated downward stage migration [1]. In turn, the number
of radical prostatectomies performed each year has also
risen and promises to continue to rise, based on projected
increases in the population size, the life expectancy (now
78 years in the USA) and fraction of the population over
the age of 65 [2]. Concurrently, the estimated prevalence of
overweight (BMI 25.0–29.9 kg/m2) and obese (BMI
C 30 kg/m2) adults aged 20–74 years in the US has also
increased steadily over the last 25 years from 15 to 31%
today [3]. Since 2000, when the da Vinci surgical system
was first introduced to the US, the absolute number and
percentage of patients with prostate cancer treated with
robotic-assisted laparoscopic radical prostatectomy
(RALP) has steadily increased. It is now estimated that
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approximately 63% of all radical prostatectomies will be
performed robotically in 2007 [4].
Over the past 5 years, reports on minimally invasive
techniques for prostate cancer have shown that patients
treated by either laparoscopic radical prostatectomy (LRP)
or RALP consistently have lower blood loss and transfu-
sion rates. Perioperative morbidity, hospital stay,
complications, and recovery are at least equal to if not
better than reports of those treated with open radical ret-
ropubic prostatectomy (RRP) [5, 6]. Studies looking at the
impact of obesity on RALP are limited and have shown
mixed results. Ahlering et al. [7] reported on a series of 100
RALPs. Obese patients with a BMI greater than 30 had
higher blood loss, complication rate, and operative times
compared to patients with a BMI less than 30. However,
other investigations have shown no differences in compli-
cation rates, margin status, hospital stay, blood loss, and
recurrence in comparison to the normal weight cohort [8–
10]. All of these reports are limited by the sample size.
We evaluated the surgical outcomes in obese versus
normal weight subjects in one of the largest single-insti-
tution robotic prostatectomy cohorts. Using our
institutional review board (IRB)-approved database of pre-
and postsurgery information collected on 1,513 RALP
patients, we report on the perioperative and clinical out-
comes in our patients with regard to BMI status.
Materials and methods
In December 2000, the Department of Urology estab-
lished a prostate cancer database. The database collection
system consists of Verity Teleform scannable forms,
image data capture, and an MS SQL Server database. All
patients with prostate cancer who presented to COH on or
after January 1, 1995 and who received at least part of
their treatment at COH were evaluated for inclusion in
this IRB-approved database. Patient consent was obtained
prior to enrollment into the database. Data were then
collected prospectively from the time of consent on
operative parameters and outcomes; 1,513 consecutive
patients enrolled in the database underwent RALP by four
surgeons at our institution between June 2003 and
November 2006. Any patient otherwise considered a
candidate for RRP was offered RALP. Body habitus was
not considered a contraindication. From June 2003 to
November 2006, 96.8% of radical prostatectomies at our
institution were performed robotically. All eligible
patients were included in the analysis without regard to
learning curve or surgeon experience. Subjects were
divided into four categories according to preoperative
BMI (kg/m2): normal (BMI \ 25), overweight (BMI 25–
29.9), mildly obese (BMI 30–34.9), and severely obese
(BMI [ 35). Height and weights were obtained from
direct measurements. Factors analyzed for this report
include: age, race, BMI, PSA, pretreatment Gleason score,
clinical stage, operative time, nerve-sparing status, spec-
imen weight, pathologic stage and grade, margin status,
intraoperative and postoperative complications (within
30 days of surgery), catheterization time, physician-
reported time to continence (use of 1 pad/day for security
purposes only), and length of hospitalization.
Surgical technique and early postoperative care
All prostatectomies were performed transperitoneally
with COH modifications to the Montsouris technique
[11]. A four-arm robot with two assistant ports for a
total of six ports was used for RALP. The fourth arm
was placed through a port that was medial to the left
anterior superior iliac spine. The bladder was mobilized
completely by bilaterally incising the peritoneum lateral
to the medial umbilical ligaments. The medial umbilical
ligaments and urachus were divided as cephalad as
possible. The endopelvic fascia was opened to gain
access to the prostatic apex and expose the deep dorsal
venous complex. The dorsal vein complex was divided
and controlled with an endovascular stapler (Ethicon
45 mm). For the urethrovesical anastomosis, one to three
posterior anastomotic sutures were interrupted (depend-
ing on surgeon preference) followed by two running
sutures from the 5 and 7 o’clock to 12 o’clock positions.
Catheters were removed on postoperative day (POD) 4 to
7 according to the practice pattern of the treating sur-
geon. No procedures were aborted and no patients
underwent open conversion.
Histopathological analysis
Surgical specimens were fixed intact in 10% neutrally
buffered formalin. The outer surface was inked to delineate
the surgical margins (black) and the left (green) and right
(blue) orientation. Prostate and seminal vesicles were
sectioned transversely at approximately 5 mm intervals,
depending on the size of the specimen. The pathologist
identified the location and extent of cancer. The presence
and location of extracapsular extension, seminal vesicle
invasion, lymph node metastasis, and histological grade
were recorded. A positive surgical margin was defined as
tumor cells reaching the inked surface. Extracapsular
extension was defined as tumor cells reaching the peri-
prostatic adipose tissue with or without a positive surgical
margin.
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Statistical analysis
Data analysis was performed using Statistical Analysis
System software (SAS Institute, Cary, NC, USA). Data
were summarized using descriptive statistics, including
means for normally distributed continuous data, medians
for nonnormally distributed continuous data, and propor-
tions for categorical data. Univariate analyses determining
group differences were performed using Pearson0s {2 test
statistic for categorical data, Student’s t-test statistic for
normally distributed continuous data, and the Kruskal–
Wallis test for nonnormally distributed continuous data.
Log-rank tests were used to assess time-dependent differ-
ences across groups (e.g., days to catheter removal and
months to continence). Missing data were excluded from
the analyses.
Results
Demographic and clinical data
Table 1 presents the initial clinical and demographic data for
all four groups of patients: normal, overweight, mildly obese,
and severely obese. The severely obese group was noted to be
significantly younger at presentation (P = 0.0001) and with
a higher mean Gleason score (P = 0.002). There was no
significant difference in clinical stage and preoperative PSA
but severely obese patients were more likely to be catego-
rized in the D’Amico [12] high-risk category preoperatively
(P = 0.002). In addition, there were a higher percentage of
African Americans in the obese and severely obese groups
whereas there was a higher percentage of Asians in the
normal BMI group (P = 0.0002).
Table 1 Baseline characteristics of prostate cancer patients receiving RAP by BMI status
Normal Overweight Mildly obese Severely obese P value
BMI \ 25 BMI 25–29.9 BMI 30–34.9 BMI 35+
n = 361 n = 794 n = 290 n = 68
Age at surgery (year), mean (std) 64.6 ± 8.0 62.6 ± 7.4 62.6 ± 7.3 61.1 ± 7.3 \0.0001
Race, N (%)
White 307 (85.0) 728 (91.7) 265 (91.4) 60 (88.2) 0.0002
Asian 39 (10.8) 37 (4.7) 13 (4.5) 2 (2.9)
Black 10 (2.8) 24 (3.0) 12 (4.1) 6 (8.8)
Other 5 (1.4) 5 (0.6) 0 (0.0) 0 (0.0)
PSA (ng/mL), median (std) 5.3 ± 11.0 5.4 ± 5.4 5.6 ± 6.5 5.5 ± 7.9 0.12
PSA group, N (%)
0–3.9 72 (20.1) 158 (20.1) 41 (14.3) 13 (19.4) 0.13
4–10 236 (65.9) 541 (68.9) 198 (69.2) 45 (67.2)
[10 50 (14.0) 86 (11.0) 47 (16.4) 9 (13.4)
Clinical stage, N (%)
T1abc 300 (83.1) 666 (84.2) 249 (85.9) 59 (86.8) 0.74
T12/3 61 (16.9) 125 (15.8) 41 (14.1) 9 (13.2)
Gleason score, N (%)
2–4 1 (0.3) 1 (0.1) 0 (0.0) 0 (0.0) 0.004
5–6 224 (62.1) 514 (65.2) 180 (62.5) 34 (50.0)
7 112 (31.0) 228 (28.9) 90 (31.3) 20 (29.4)
8–10 24 (6.7) 46 (5.8) 18 (6.3) 14 (20.6)
Gleason score, mean (std) 6.4 ± 0.7 6.4 ± 0.7 6.4 ± 0.7 6.8 ± 0.9 0.002
Risk group, N (%)
Low risk 195 (54.5) 463 (59.4) 154 (54.0) 31 (46.3) 0.002
Intermediate risk 125 (34.9) 250 (32.1) 107 (37.5) 20 (29.9)
High risk 38 (10.6) 66 (8.5) 24 (8.4) 16 (23.9)
Surgeon, N (%)
A 158 (43.8) 349(44.0) 106 (36.6) 27 (39.7) 0.30
B 142 (39.3) 305 (38.4) 117 (40.3) 27 (39.7)
C 46 (12.7) 94 (11.8) 41 (14.1) 9 (13.2)
D 15 (4.2) 46 (5.8) 26 (9.0) 5 (7.4)
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Surgical and pathologic outcomes
Outcomes according to BMI are summarized in Table 2. In
comparison to the normal and overweight groups, the obese
and mildly obese patients had significantly longer operative
times (P \ 0.0001), greater intraoperative blood loss
(P \ 0.0001), and were more likely to undergo a non-nerve-
sparing procedure (P = 0.02). There were no significant
differences in intraoperative or perioperative complications,
transfusion rates, median time to continence or hospital stay.
In addition, there was no significant difference in pathologic
stage, grade, or margin status (Table 3).
Discussion
As RALP becomes more widely available, robotic sur-
geons continue to explore the challenges and capabilities of
Table 2 Operative and oncological characteristics of prostate cancer patients receiving RAP by BMI status
Normal Overweight Mildly obese Severely obese P value
BMI \ 25 BMI 25–29.9 BMI 30–34.9 BMI 35+
n = 361 n = 794 n = 290 n = 68
Operation time (hours), mean (std) 2.7 ± 0.7 2.8 ± 0.7 3.1 ± 0.9 3.3 ± 1.0 \0.0001
Nerve sparing, N (%)
Nerve sparing, bilateral 317 (88.1) 700 (88.4) 244 (84.4) 51 (75.0) 0.02
Nerve sparing, unilateral 19 (5.3) 46 (5.8) 17 (5.9) 6 (8.8)
Non-nerve-sparing 24 (6.7) 46 (5.8) 28 (9.7) 11 (16.2)
Estimated blood loss (mL), median (std) 200 ± 172 200 ± 180 250 ± 235 250 ± 202 \0.0001
Blood transfusion, N (%)
No 344 (97.7) 767 (98.3) 280 (99.3) 66 (98.5) 0.49
Yes 8 (2.3) 13 (1.7) 2 (0.7) 1 (1.5)
Major complications (intraop.), N (%)
No 357 (98.9) 788 (99.2) 288 (99.3) 68 (100.0) 0.79
Yes 4 (1.1) 6 (0.8) 2 (0.7) 0 (0.0)
Major complications (periop.), N (%)
No 293 (84.7) 641 (84.1) 228 (81.1) 55 (82.1) 0.62
Yes 53 (15.3) 121 (15.9) 53 (18.9) 12 (17.9)
Specimen wt (grams), mean (std) 52.2 ± 21.8 54.6 ± 21.4 57.0 ± 25.8 51.7 ± 19.7 0.04
Path T stage, N (%)
T0 2 (0.6) 3 (0.4) 1 (0.4) 0 (0.0) 0.58
pT1/2 307 (84.0) 691 (87.1) 242 (83.5) 55 (80.9)
pT3 52 (14.4) 99 (12.5) 47 (16.2) 13 (19.1)
Gleason score, N (%)
5–6 152 (42.8) 373 (47.8) 118 (41.7) 22 (36.1) 0.08
7 189 (53.2) 368 (47.3) 145 (51.2) 33 (54.1)
8–10 14 (3.9) 38 (4.9) 20 (7.1) 6 (9.8)
Gleason score, mean (std) 6.6 ± 0.6 6.6 ± 0.7 6.7 ± 0.7 6.8 ± 0.8 0.06
Path node status, N (%)
Negative 210 (98.1) 458 (98.9) 166 (98.8) 42 (97.7) 0.79
Positive 4 (1.9) 5 (1.1) 2 (1.2) 1 (2.3)
SV invasion, N (%)
Negative 339 (93.9) 748 (94.4) 265 (92.3) 62 (91.2) 0.49
Positive 22 (6.1) 44 (5.6) 22 (7.7) 6 (8.8)
Surgical margins, N (%)
Negative 279 (77.3) 595 (75.2) 215 (74.4) 46 (68.7) 0.4
Positive 82 (22.7) 196 (24.8) 74 (25.6) 21 (31.3)
Extracapsular extension, N (%)
Negative 320 (88.6) 714 (90.2) 254 (87.9) 56 (82.4) 0.21
Positive 41 (11.4) 78 (9.9) 35 (12.1) 12 (17.7)
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the da Vinci system, including those pertaining to obesity.
Some studies have found that obesity is associated with
increased technical difficulty and higher complication rates
in open [13] and laparoscopic prostate surgery [14, 15].
During open radical prostatectomy, abdominal fat can limit
surgical exposure and access to the prostate and may
increase the likelihood of greater EBL and intraoperative
complications. Although surgical visualization of the rad-
ical prostatectomy field is magnified in laparoscopic
surgery, instrument mobility within the ports is limited in
obese patients [8]. Indeed, RALP in obese patients has
been reported to be associated with longer operative times,
higher estimated blood loss and complications, and delayed
recovery of continence [7–9].
Oncologically, increasing obesity defined by BMI has
been associated with an increased risk of more aggressive
prostate cancer and an increase in prostate cancer mortality
[16–18]. This may be related to differences in several
hormonal and metabolic factors seen in obese men versus
normal weight men. In our cohort we noticed that mildly
and severely obese patients present at an earlier age with
more aggressive disease as defined by the D’Amico risk
stratification. This may explain why our obese patients
were more likely to undergo a non-nerve-sparing
procedure.
Compared to non-obese men, higher biochemical failure
rates have been reported among obese men [16]. These
higher recurrence rates may not only be influenced by a
more aggressive disease but also by the technical surgical
difficulties prevalent in obese patients. Most surgical series
found that obese men undergoing radical prostatectomy,
either open or perineal, had a higher positive margin rate
[19–21]; however, there is limited literature evaluating this
risk in minimally invasive series. In our RALP series,
obese men did not differ significantly in margin status. This
may be related to the specific surgical technique or to the
addition of the da Vinci system when compared to open or
laparoscopic series.
There was an increasing trend in mean operative time as
BMI increased, which is consistent with other previous
LRP and RALP reports [8, 10, 14]. Though we did not time
each step in the surgical procedure, other RALP series in
obese men have reported difficulties in urethral dissection,
urethral anastomosis, port placement [8], and instrument
positioning [9]. Obese men tend to have thicker abdominal
walls, which require longer surgical instruments and
adjustment of the robotic port sites [9]. In addition to a
thicker abdominal wall, more intraperitoneal, periprostatic,
and pelvic fat in obese men tends to obstruct the visual field
and make it more difficult to reach the target organ. These
obstacles may explain the higher blood loss and longer
operative time seen in severely obese men in our series and
are similar to what other studies found [8, 10]. However,
our complication and transfusion rates, hospital stay,
margin status, and time to catheter removal were not sig-
nificantly different in obese versus non-overweight
patients.
Our study is currently the largest series to evaluate the
impact of obesity on RALP. Limitations of our study
include that it is not a randomized prospective analysis, the
majority of our patients were Caucasian, and that obesity
was a one-time measurement. In addition, since we are
primarily a referral center, our population of obese patients
may be biased in that only those patients felt to be good
surgical candidates by the referring physician are subse-
quently referred to us. Patients felt to be poor surgical
candidates and thus at somewhat higher risk for operative
complications may have been referred for other treatment
modalities.
Conclusion
While it has been demonstrated that obese patients can
safely undergo minimally invasive surgery, tolerating the
anesthetic and Trendelenburg position [22], we now
Table 3 Postoperative characteristics of prostate cancer patients receiving RAP by BMI status
Normal Overweight Mildly Obese Severely Obese P value
BMI \ 25 BMI 25–29.9 BMI 30–34.9 BMI 35+
n = 361 n = 794 n = 290 n = 68
Hospital stay, N (%)
0–2 306 (84.8) 691 (87.1) 243 (83.8) 55 (80.9) 0.32
3+ 55 (15.2) 103 (12.9) 47 (16.2) 13 (19.1)
Hospital stay (days), median (std) 2 ± 1.7 2 ± 1.5 2 ± 1.6 2 ± 1.1 0.09
Days to catheter removal, median (std error) 7 ± 7.9 7 ± 4.0 7 ± 4.7 7 ± 9.4 0.45*
Months to continence, median (std error) 3.7 ± 0.5 2.9 ± 0.3 4.0 ± 0.4 4.2 ± 0.6 0.22*
* Log-rank P value
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demonstrate that obese patients can also be safely consid-
ered as candidates for robotic assisted laparoscopic radical
prostatectomy with no significant increase in perioperative
complications, transfusion rates, or length of hospital stay.
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